Recursion Pharmaceuticals, Inc. RXRX Operating Income
Operating Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s operating income?
- Recursion Pharmaceuticals, Inc. (RXRX) reported operating income of -$128.51M in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s operating income changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s operating income increased by 32.8% year-over-year, from -$191.37M to -$128.51M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s operating income?
- Over 4 years (2021 to 2025), Recursion Pharmaceuticals, Inc.'s operating income has grown at a 37.2% compound annual growth rate (CAGR), from -$182.78M to -$648.13M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.